BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. Mhibik M, Gaglione EM, Eik D, Kendall EK, et al. Blood 2021;138:1843-1854.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mhibik M, Gaglione EM, Eik D, Kendall EK, et al. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. Blood 2021;138:1843-1854.
PMID: 34046681